Floatz logo

sl-172154

Primary Peritoneal Carcinoma

Shattuck Labs, Inc.Phase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Epirubicin
Roswell Park Cancer Institute
Phase 3BB
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 3BB
Inno-206
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

sl-172154 is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
fallopian tube carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →